CEMI - Chembio nabs BARDA contract for rapid respiratory antigen panel test

The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority ((BARDA)) has awarded a $12.7M contract to Chembio Diagnostics ([[CEMI]] +8.8%) to support the development and U.S. emergency use nod for a rapid DPP respiratory antigen panel point-of-care test system for the upcoming flu season.The panel will be designed to simultaneously detect and differentiate antigens from influenza A & B and SARS-CoV-2 in ~20 minutes when performed on the company's DPP Micro Reader analyzer.A second portion of the contract will support the verification, process validation and production of clinical validation data that will be included in a 510(k) application to the FDA seeking clearance and CLIA waiver for the DPP SARS-CoV-2 Antigen test system that can generate a result in ~20 minutes from a nasal swab.

For further details see:

Chembio nabs BARDA contract for rapid respiratory antigen panel test